Personalized psychiatry: Many questions, fewer answers

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 6, 2013, Pages 363-365

  Alda, Martin ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PRECISION; EDITORIAL; EXPECTATION; HEALTH CARE COST; HEALTH CARE PRACTICE; HUMAN; MENTAL DISEASE; MORBIDITY; PERSONALIZED MEDICINE; PREDICTION; PSYCHIATRY; SOCIAL STIGMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ATTITUDE OF HEALTH PERSONNEL; HEALTH CARE COSTS; HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; SYMPTOM ASSESSMENT;

EID: 84886653243     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.130221     Document Type: Editorial

References (16)

1. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 2012;106:1100-6.
2. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med 2006;355:920-7.
3. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Global Burden of disease and Injury Series Vol. 1. Harvard University Press, Cambridge (MA); 1996.
4. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
5. Tansey KE, Guipponi M, Perroud N, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 2012;9:e1001326.
6. Angst J. A clinical analysis of the effects of tofranil in depression: longitudinal and follow-up studies. Treatment of blood-relations. Psychopharmacologia 1961;2:381-407.
7. Pare CMB. Differentiation of two genetically specific types of depression by the response to antidepressant drugs. Humangenetik 1970;9:199-201.
8. Franchini L, Serretti A, Gasperini M, et al. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998;32:255-9.
9. Remick RA, Sadovnick AD, Gimbarzevsky B, et al. Obtaining a family psychiatric history: Is it worth the effort? Can J Psychiatry 1993;38:590-4.
10. Kaiser J. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Science 2012;335:645.
11. Garnham J, Munro A, Slaney C, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 2007;104:185-90.
12. Vieta E. Pros and cons of specialised care in bipolar disorder: an international perspective. Br J Psychiatry 2013;202:170-1.
13. Španiel F, Vohlídka P, Hrdlicka J, et al. ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Res 2008;98:312-7.
14. Španiel F, Hrdlicka J, Novák T, et al. Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study. J Psychiatr Pract 2012;18:269-80.
15. Dolgin E. Mutation-specific cystic fibrosis treatments on verge of approval. Nat Med 2011;17:396-7.
16. Leuchter AF, Cook IA, Uijtdehaage SH, et al. Brain structure and function and the outcomes of treatment for depression. J Clin Psychiatry 1997;58(Suppl 16):22-31.